James A. DeCaprio, MD

home / authors / james-a-decaprio-md

Articles

Ann W. Silk, MD, MS, codirector, the Merkel Cell Carcinoma Center of Excellence, physician, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

Ann W. Silk, MD, MS;James A. DeCaprio, MD
February 14th 2024

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Read More

James A. DeCaprio, MD, of Dana-Farber Cancer Institute

Dr. DeCaprio on Raising Awareness in Merkel Cell Carcinoma

James A. DeCaprio, MD
May 25th 2021

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Read More

Latest Updated Articles

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Published: May 27th 2024 | Updated: September 13th 2024
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
Published: September 17th 2024 | Updated: September 21st 2024
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer